URGO Recherche, Innovation et Développement

URGO Recherche, Innovation et Développement (URGO RID) is the dedicated research and innovation arm of the Urgo Group, a prominent French healthcare company specializing in advanced wound care and skin healing. The entity is renowned for developing the Technology Lipido-Colloid (TLC), a healing matrix used across a wide range of dressings to promote fibroblast proliferation and wound recovery. URGO RID is currently spearheading the "Genesis" project, a major biotechnological initiative aimed at developing artificial skin to treat severe burns and chronic wounds. Their work integrates materials science, biology, and clinical research to provide solutions for complex pathologies such as diabetic foot ulcers and venous leg ulcers. Based in Chenôve, France, the organization operates at the intersection of medical devices and regenerative medicine.